조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C35H58O9
CAS 번호:
Molecular Weight:
622.83
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Beilstein/REAXYS Number:
4730700
MDL number:
제품 이름
Bafilomycin A1 from Streptomyces griseus, ≥90% (HPLC)
Quality Level
assay
≥90% (HPLC)
form
film
antibiotic activity spectrum
fungi
mode of action
DNA synthesis | interferes, enzyme | inhibits
storage temp.
−20°C
SMILES string
CO[C@H]1\C=C\C=C(C)\C[C@H](C)[C@H](O)[C@H](C)\C=C(C)\C=C(OC)C(=O)OC1[C@@H](C)[C@@H](O)[C@H](C)[C@@]2(O)C[C@@H](O)[C@H](C)[C@H](O2)C(C)C
InChI
1S/C35H58O9/c1-19(2)32-24(7)27(36)18-35(40,44-32)26(9)31(38)25(8)33-28(41-10)14-12-13-20(3)15-22(5)30(37)23(6)16-21(4)17-29(42-11)34(39)43-33/h12-14,16-17,19,22-28,30-33,36-38,40H,15,18H2,1-11H3/b14-12+,20-13+,21-16+,29-17-/t22-,23+,24-,25-,26-,27+,28-,30-,31+,32+,33+,35+/m0/s1
InChI key
XDHNQDDQEHDUTM-JQWOJBOSSA-N
General description
Chemical structure: macrolide
Application
Bafilomycin A1 has been used:
- as an autophagy inhibitor to study its effects on hepatic steatosis in human hepatocytes
- as a vacuolar-type H+ -ATPase inhibitor to study its effects on the cell viability, percentage of PI-positive cells, and glucose-stimulated insulin secretion (GSIS) in mice INS-1 cells
- as a vacuolar-type H+ -ATPase inhibitor to study its effects on tau degradation in human SH-SY5Y cells
Biochem/physiol Actions
A specific inhibitor of vacuolar type H+-ATPase (V-ATPase) in animal cells, plant cells and microorganisms.
Bafilomycin A1 inhibits autophagosome-lysosome fusion and autolysosome acidification, the steps involved in the autophagic process that is required for maintaining functional autophagic flux and cellular homeostasis.
Specific inhibitor of vacuolar type H+-ATPase (V-ATPase).
저장 등급
11 - Combustible Solids
wgk
WGK 3
ppe
dust mask type N95 (US), Eyeshields, Gloves
문서
We presents an article on Autophagy in Cancer Promotes Therapeutic Resistance
관련 콘텐츠
Autophagy in Cancer
ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis
He Q, et al.
Journal of Molecular Endocrinology, 57(4) (2016)
Jens Niewoehner et al.
Neuron, 81(1), 49-60 (2014-01-15)
Although biotherapeutics have vast potential for treating brain disorders, their use has been limited due to low exposure across the blood-brain barrier (BBB). We report that by manipulating the binding mode of an antibody fragment to the transferrin receptor (TfR)
T Yoshimori et al.
The Journal of biological chemistry, 266(26), 17707-17712 (1991-09-15)
Bafilomycin A1 is known as a strong inhibitor of the vacuolar type H(+)-ATPase in vitro, whereas other type ATPases, e.g. F1,F0-ATPase, are not affected by this antibiotic (Bowman, E.M., Siebers, A., and Altendorf, K. (1988) Proc. Natl. Acad. Sci. U.S.A.